Prognostic significance of C‐reactive protein in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

Shun Kaneko(Tokyo Medical and Dental University), Taro Watabe(Ome Municipal General Hospital), Kento Inada(Tokyo Medical and Dental University), Takashi Fujii(Tokyo Metropolitan Hiroo Hospital), Keiichi Akahoshi(Tokyo Medical and Dental University), Sho Watanabe(Chiba Cancer Center), Taro Shimizu(Dokkyo Medical University), Jun Tsuchiya(Tokyo Medical and Dental University), Akiko Kusano‐Kitazume(Tokyo Metropolitan Tama Medical Center), Hideki Watanabe(Yokosuka Kyosai Hospital), Miyako Murakawa(Tokyo Medical and Dental University), Mina Nakagawa(Tokyo Medical and Dental University), Sei Kakinuma(The University of Tokyo), Kozue Uchidate(JA Toride Medical Center), Takehito Asakawa(Yokohama Municipal Minato Red Cross Hospital), Shinya Oooka(Showa General Hospital), Isamu Shibata(National Hospital Organization), Tomohiro Mochida(Tokyo Medical and Dental University), Ryuichi Okamoto(Tokyo Medical and Dental University), Fukiko Kitahata‐Kawai(Tokyo Medical and Dental University), Keiya Watakabe(Tokyo Medical and Dental University), Yasuhiro Asahina(Tokyo Medical and Dental University), Shunsuke Ueyama(Tsuchiura Kyodo General Hospital), Chiaki Maeyashiki(Musashino Red Cross Hospital), Sayuri Nitta(Tokyo Medical and Dental University), Yasuhiro Iizuka(Kashiwa Municipal Hospital), Minoru Tanabe(Tokyo Institute of Technology), Ayako Sato(Tokyo Metropolitan Bokutoh Hospital), Yuko Karakama(Kure Kyosai Hospital), Masato Miyoshi(Tokyo Medical and Dental University)
Hepatology Research
December 22, 2023
Cited by 15


Related Papers